Forced Vital Capacity in Idiopathic Pulmonary Fibrosis - FDA Review of Pirfenidone and Nintedanib

被引:248
作者
Karimi-Shah, Banu A. [1 ]
Chowdhury, Badrul A. [1 ]
机构
[1] US FDA, Div Pulm Allergy & Rheumatol Prod, Off New Drugs, Ctr Drug Evaluat & Res, Silver Spring, MD 20993 USA
关键词
D O I
10.1056/NEJMp1500526
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
[No abstract available]
引用
收藏
页码:1189 / 1191
页数:3
相关论文
共 4 条
[1]   Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis [J].
Collard, HR ;
King, TE ;
Bartelson, BB ;
Vourlekis, JS ;
Schwarz, MI ;
Brown, KK .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2003, 168 (05) :538-542
[2]  
FDA, Drugs@FDA FDA-Approved Drugs
[3]  
Karimi-Shah BA, 2010, PULM ALL DRUGS ADV C
[4]   Idiopathic Pulmonary Fibrosis: Clinically Meaningful Primary Endpoints in Phase 3 Clinical Trials [J].
Raghu, Ganesh ;
Collard, Harold R. ;
Anstrom, Kevin J. ;
Flaherty, Kevin R. ;
Flemings, Thomas R. ;
King, Talmadge E., Jr. ;
Martinee, Fernando J. ;
Brown, Kevin K. .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2012, 185 (10) :1044-1048